title: [Metastatic prostate cancer].
abstract: Metastatic prostate cancer is an uncurable disease. Treatment is only palliative. Median survival of patients is 3 years. Prostate cancer is an hormonodependent cancer, androgen blockade is the most active treatment. However hormone resistance occurs after a median interval of 2 years. The major symptom is pain, others are urinary obstruction, neurological complications of bone metastases and hematological disorders. Androgen deprivation is the first-line treatment, impotency and osteoporosis being the main side effects. Other treatments are radiotherapy, radiopharmaceutics and chemotherapy. The most important treatment issue is quality of life.
authors.affiliation: Département de Cancérologie médicale, Centre Léon Bérard, 69373 Lyon 08. droz@lyon.fnclcc.fr
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Droz
authors.forename: Aude
authors.initials: A
authors.lastname: Flechon
authors.forename: Catherine
authors.initials: C
authors.lastname: Terret
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D001918:Brachytherapy; D007172:Erectile Dysfunction / Q000139:chemically induced; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D010024:Osteoporosis / Q000139:chemically induced; D010166:Palliative Care; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D011788:Quality of Life; D013997:Time Factors
chemical_list: D000726:Androgen Antagonists